Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
CRISPR Therapeutics
About
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.
- 101 - 250
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $29M
- Industries
- Biopharma,Biotechnology,Genetics,Medical
- Founded date
- Jan 1, 2013
- Number Of Employee
- 101 - 250
- Operating Status
- Active
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing.CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 30, 2015 | Series B | $29M | 2 |
|
— | Detail |
| Apr 29, 2015 | Series A | $35M | 1 | — | — | Detail |
| Apr 24, 2014 | Series A | $25M | 1 |
Versant Ventures
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series B |
|
Versant Ventures
|
— | Series B |
